Navigation Links
Genomic Health Announces Eight Oncotype DX(R) Studies to Be Presented at 30th Annual San Antonio Breast Cancer Symposium
Date:12/7/2007

REDWOOD CITY, Calif., Dec. 7 /PRNewswire-FirstCall/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that results from eight studies of the company's Oncotype DX(R) breast cancer test are scheduled to be presented at the 30th Annual San Antonio Breast Cancer Symposium, taking place December 13-16, 2007. Oncotype DX is a multi-gene expression test that physicians use to predict the likelihood of recurrence and the likelihood of chemotherapy benefit for a large portion of early-stage breast cancer patients.

Following are details for each embargoed session (all times are Central Standard Time):

Thursday, Dec. 13, 2007, 9:15 to 9:30 a.m.

Abstract #10

Late-Breaking oral presentation: "Prognostic and predictive value of the

21-gene Recurrence Score assay in postmenopausal, node-positive, ER

positive breast cancer.

"Presenter: Kathy S. Albain, M.D.

Thursday, Dec. 13, 2007, 5 to 7 p.m.

Abstract #1043

Poster presentation: Recurrence Score by Oncotype DX evaluated on the

primary breast tumor predicts the 2-year survival after first relapse.

Presenter: Giampaolo Bianchini, M.D.

Abstract #1092

Poster presentation: "Prospective multi-center study of the impact of the

21-gene Recurrence Score assay on patient satisfaction, anxiety and

decisional conflict for adjuvant breast cancer treatment

selection.

"Presenter: Patricia B. Mumby, Ph.D.

Friday, Dec. 14, 7 to 9 a.m.

Abstract #2061

Poster presentation: "A retrospective analysis of the impact of Oncotype

DX low Recurrence Score results on treatment decisions in a single

academic breast cancer center.

"Presenter: Hongmei Liang, M.D., Ph.D.

Friday, Dec. 14, 5 to 7 p.m.

Abstract #3028

Poster presentation: "Gene expression by standardized quantitative RT-PCR

in the special histologic subtypes of estrogen receptor positive invasive

breast cancer.

"Presenter: Frederick L. Baehner, M.D.

Abstract #3082

Poster presentation: "Evaluation of practice patterns in the treatment of

node-negative, hormone-receptor positive breast cancer patients with the

use of the Oncotype DX assay at the University of Pennsylvania.

"Presenter: Christopher Erb, M.D., Ph.D.

Saturday, Dec. 15, 4 to 4:15 p.m.

Abstract #63

Oral presentation: "Prognostic utility of the 21-gene assay

compared with Adjuvant! in hormone receptor (HR) positive operable breast

cancer with 0-3 positive axillary nodes treated with adjuvant

chemohormonal therapy (CHT): an analysis of intergroup trial

E2197.

"Presenter: Lori J. Goldstein, M.D.

Saturday, Dec. 15, 5 to 7 p.m.

Abstract #5029

Poster presentation: "Estrogen receptor and breast cancer survival in a

Kaiser Permanente population-based study: comparison of quantitative

reverse transcriptase polymerase chain reaction and

immunohistochemistry.

"Presenter: Laurel A. Habel, M.D.

About Oncotype DX(R)

Oncotype DX is the first diagnostic multi-gene expression test commercially available that has clinical evidence validating its ability to predict the likelihood of breast cancer recurrence, the likelihood of breast cancer survival and the likelihood of chemotherapy benefit. Oncotype DX has been extensively evaluated in multiple independent studies involving more than 3,300 breast cancer patients, including a large validation study published in The New England Journal of Medicine and a chemotherapy benefit study published in the Journal of Clinical Oncology. To date, nearly 7,000 physicians have ordered more than 40,000 tests, and health plans covering over 50 percent of U.S. insured lives provide reimbursement for Oncotype DX through contracts, agreements and policy decisions. The American Society of Clinical Oncologists (ASCO) recommends the use of Oncotype DX for patients with node-negative breast cancer that is estrogen-receptor positive and/or progesterone-receptor positive. For more information about Oncotype DX, please visit http://www.oncotypedx.com.

About Genomic Health

Genomic Health, Inc. (Nasdaq: GHDX) is a life science company focused on the development and commercialization of genomic-based clinical laboratory services for cancer that allow physicians and patients to make individualized treatment decisions. In 2004, Genomic Health launched its first test service, Oncotype DX(TM), which has been shown to predict the likelihood of breast cancer recurrence and the likelihood of chemotherapy benefit in early-stage breast cancer patients. The company was founded in 2000 and is located in Redwood City, California. For more information, please visit http://www.genomichealth.com.

NOTE: Genomic Health, the Genomic Health logo, Oncotype, Oncotype DX and Recurrence Score are trademarks or registered trademarks of Genomic Health, Inc. All other trademarks and service marks are the property of their respective owners.


'/>"/>
SOURCE Genomic Health, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
2. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
3. Personalized Medicine - The Genomic Revolution in Cardiac Care
4. Virogenomics, Inc. Awarded $2 Million National Institute of Standards and Technology (NIST) Advanced Technology Program Grant to Develop Integrated Diagnostic Biosensors
5. Genomic Health Announces Preliminary Results From a Study of Oncotype DX(TM) in Node-Positive Breast Cancer Patients
6. Microarray Sequence Capture Speeds Large-Scale Resequencing of Targeted Genomic Regions
7. BiPar Genomic Biomarker Data Demonstrate Overexpression of PARP-1 Gene in Multiple Cancer Types
8. Baxter Awarded Pandemic Advanced Supply Contract from the Department of Health
9. BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health
10. Tone Deafness Explained, from the Harvard Health Letter
11. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) ... Improvements Act of 1976, as amended ("HSR"), with respect ... Nasdaq: CPXX ) expired effective June 24, ... As previously announced on May 31, 2016, Jazz Pharmaceuticals ... which Jazz Pharmaceuticals has commenced a tender offer for ...
(Date:6/24/2016)... SAN FRANCISCO, Calif. , June 24, 2016 ... GBT ), a biopharmaceutical company developing novel therapeutics ... significant unmet needs, today announced the closing of ... shares of common stock, at the public offering ... shares in the offering were offered by GBT. ...
(Date:6/24/2016)... June 24, 2016 Dehaier Medical Systems Ltd. ... which develops, markets and sells medical devices and wearable ... signed a strategic cooperation agreement with Hongyuan Supply Chain ... Chain") on June 20, 2016, to develop Dehaier,s new ... cooperation agreement, Dehaier will leverage Hongyuan Supply Chain,s sales ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... ... Austin residents seeking Mohs surgery services, can now turn to Dr. Jessica ... Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to include Mohs ... Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn Goldstein, ...
(Date:6/25/2016)... Oklahoma (PRWEB) , ... June 25, 2016 , ... ... both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures ... Oklahoma City area —Johnson is one of the first doctors to perform the ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle ... chronic pain and the benefits of holistic treatments, Serenity Recovery Center of ... Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the red ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA ... the Road To Recovery® program to drive cancer patients to and from their cancer ... ensure the highest quality of life and ongoing independence. Getting to and from ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® ... Group (TGIG), has initiated cultivation and processing operations at its production facility, and ... Nevada. , Puradigm is the manufacturer of a complete system of proactive air ...
Breaking Medicine News(10 mins):